Aviptadil
(Synonyms: 阿肽地尔; Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)) 目录号 : GC14472
Aviptadil是一种具有28个氨基酸的神经递质，是一种血管活性肠多肽（VIP）类似物，具有有效的血管舒张作用，能够诱导肺血管扩张，抑制血管平滑肌细胞增殖、血小板聚集。
Cas No.:40077-57-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Aviptadil is a 28-amino acid neurotransmitter and a vasoactive intestinal polypeptide (VIP) analog. It has an effective vasodilator effect, can induce pulmonary vasodilation, and inhibit vascular smooth muscle cell proliferation and platelet aggregation[1, 2]. Aviptadil can be used in the study of pulmonary fibrosis, pulmonary hypertension, and respiratory failure caused by SARS-CoV-2[3].
In vivo, Aviptadil (500μg/kg) was intraperitoneally injected into rats with pulmonary hypertension (PHT) for 3 weeks, completely preventing and significantly reversing monocrotaline (MCT)-induced pulmonary hypertension PAH, and had a synergistic effect with bosentan[4]. Aviptadil (150μg/kg/day) was intraperitoneally injected into rats with pulmonary hypertension for 4 weeks, eliminating bronchial hyperresponsiveness (BHR) and having bronchodilating properties[5]. Aviptadil (3μg/kg) was intravenously injected into rats with lung transplantation model and improved the rat lung transplantation reperfusion injury[6].
References:
[1] Hu J, Xu Q, McTiernan C, et al. Novel targets of drug treatment for pulmonary hypertension[J]. American Journal of Cardiovascular Drugs, 2015, 15: 225-234.
[2] O'Callaghan D S, Jaïs X, Montani D, et al. A Look to the Future: Potential Therapeutic Options for Pulmonary Arterial Hypertension[J]. The Annals of Respiratory Medicine, 2009, 1(1): 1.
[3] Chakraborty D, Choudhury S, Lahiry S. Aviptadil-class effect of a synthetic vasoactive intestinal peptide as a treatment option in COVID-19 patients with severe respiratory failure[J]. Indian Journal of Respiratory Care, 2022, 11(1): 5-5.
[4] Hamidi S A, Lin R Z, Szema A M, et al. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension[J]. Respiratory research, 2011, 12: 1-7.
[5] Habre W, Albu G, Janosi T Z, et al. Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension[J]. Respiratory research, 2011, 12: 1-8.
[6] Nagahiro I, Yano M, Boasquevisque C H, et al. Vasoactive intestinal peptide ameliorates reperfusion injury in rat lung transplantation[J]. The Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation, 1998, 17(6): 617-621.
Aviptadil是一种具有28个氨基酸的神经递质，是一种血管活性肠多肽（VIP）类似物，具有有效的血管舒张作用，能够诱导肺血管扩张，抑制血管平滑肌细胞增殖、血小板聚集[1, 2]。Aviptadil能够用于肺纤维化、肺动脉高压、SARS-CoV-2引起呼吸衰竭等研究[3]。
在体内，Aviptadil（500μg/kg）通过腹腔注射治疗肺动脉高压（PHT）大鼠3周，完全预防并显著逆转了野百合碱（MCT）诱发的肺动脉高压PAH，并且和波生坦（Bosentan）具有协同作用[4]。Aviptadil（150μg/kg/day）通过腹腔注射治疗肺动脉高压大鼠4周，消除了支气管高反应性（BHR），具有支气管扩张的特性[5]。Aviptadil（3μg/kg）通过静脉注射治疗肺移植模型大鼠，改善了大鼠的肺移植再灌注损伤[6]。
| Animal experiment [1]: | |
Animal models | Sprague Dawley rats |
Preparation Method | The study was designed to test 3 objectives: (1) Prevention by Aviptadil: Two groups of rats were injected with monocrotaline (MCT) (a single s.c. injection of 60mg/kg). Group 1 rats received no additional treatment; group 2 rats received Aviptadil at 500μg/kg, i.p. (in 0.2mL PBS), every other day for 3 weeks, beginning the same day as MCT, for a total of 10 injections. A third group of 10 rats, serving as controls, received neither MCT nor Aviptadil. Survival was monitored for 45 days in a fourth group of 8 rats that received a single dose of MCT plus Aviptadil. (2) Reversal by Aviptadil or Bosentan: A group of 10 rats received Aviptadil at 500μg/kg, i.p., every other day for 3 weeks, beginning 3 weeks after the injection of MCT, i.e., after PAH pathology had already developed. Another group received Bosentan at 300mg/kg/day, as food admix for 3 weeks, beginning 3 weeks after MCT. (3) Reversal by combination therapy: Three weeks after MCT injection, another group of rats received both Aviptadil and Bosentan, as above, also for 3 weeks. |
Dosage form | 500μg/kg; i.p. |
Applications | Aviptadil completely prevented and significantly reversed MCT-induced pulmonary arterial hypertension (PAH). Aviptadil and Bosentan have synergistic effects. |
References: | |
| Cas No. | 40077-57-4 | SDF | |
| 别名 | 阿肽地尔; Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine) | ||
| 分子式 | C147H238N44O42S | 分子量 | 3325.83 |
| 溶解度 | Soluble 1 mg/ml in water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3007 mL | 1.5034 mL | 3.0068 mL |
| 5 mM | 0.0601 mL | 0.3007 mL | 0.6014 mL |
| 10 mM | 0.0301 mL | 0.1503 mL | 0.3007 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet